Angelalign Technology's ROCE trend is uninspiring. Despite reinvestment for growth, sales remain stagnant. The stock has dropped 43% in a year, making investors wary. It doesn't seem to have multi-bagger potential.
Despite Angelalign Technology's lower-than-average ROE compared to the industry standard of 10%, its impressive earnings growth rate indicates that the company's management may have made strategic decisions that effectively utilize its profits.
时代天使股票讨论区
关键要点:
1。预计中国隐形正畸行业长期病例数量的复合年增长率...
暂无评论